Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 6135040

Antihistamines and sedation.

A N Nicholson
View original source ↗Export metadata ↓

Abstract

With careful use of antihistamines central effects may be minimised or even largely avoided while adequate peripheral antihistaminic activity is preserved. Tolerance to central effects may develop quickly with some drugs, so that sedation is no longer troublesome after a few days. With sustained-release antihistamines, early-evening dosage may provide sufficient activity, without sedation, the next day. For patients in whom daytime sedation is troublesome three drugs, astemizole, mequitazine, and terfenadine, are likely to prove useful. However, the response of the individual patient cannot be predicted, and the possibility of sedation can never be completely excluded.

Explore related subjects

AstemizoleBenzhydryl CompoundsBenzimidazolesBlood-Brain BarrierBrainHistamine H1 AntagonistsHumansPhenothiazinesSleep StagesTerfenadineWakefulnessJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A N Nicholson. 1983-07-23. Antihistamines and sedation.. https://doi.org/10.1016/s0140-6736(83)90185-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide.

The relevance of a point mutation at the C-terminal end of the S6 helix (F468) and the introduction of C-type inactivation in the blockage of hEag1 channels by astemizole, imipramine and dofetilide was tested. C-type inactivation decreased block by astemizole and dofetilide but not imipramine, suggesting different binding sites in the channel. F468C mutation increased IC(50) for astemizole and imipramine but in contrast to HERG channels, only slightly for dofetilide. Together with measurements on recovery of blocking, our observations indicate that the mechanism of hEag1 blockage by each of these drugs is different, and suggest relevant structural differences between hEag1 and HERG channels.

Astemizole↗
PubMed2004

Mechanism of block of hEag1 K+ channels by imipramine and astemizole.

Ether à go-go (Eag; KV10.1) voltage-gated K+ channels have been detected in cancer cell lines of diverse origin and shown to influence their rate of proliferation. The tricyclic antidepressant imipramine and the antihistamine astemizole inhibit the current through Eag1 channels and reduce the proliferation of cancer cells. Here we describe the mechanism by which both drugs block human Eag1 (hEag1) channels. Even if both drugs differ in their affinity for hEag1 channels (IC50s are approximately 2 microM for imipramine and approximately 200 nM for astemizole) and in their blocking kinetics, both drugs permeate the membrane and inhibit the hEag1 current by selectively binding to open channels. Furthermore, both drugs are weak bases and the IC50s depend on both internal an external pH, suggesting that both substances cross the membrane in their uncharged form and act from inside the cell in their charged forms. Accordingly, the block by imipramine is voltage dependent and antagonized by intracellular TEA, consistent with imipramine binding in its charged form to a site located close to the inner end of the selectivity filter. Using inside- and outside-out patch recordings, we found that a permanently charged, quaternary derivative of imipramine (N-methyl-imipramine) only blocks channels from the intracellular side of the membrane. In contrast, the block by astemizole is voltage independent. However, as astemizole competes with imipramine and intracellular TEA for binding to the channel, it is proposed to interact with an overlapping intracellular binding site. The significance of these findings, in the context of structure-function of channels of the eag family is discussed.

Astemizole↗